FindTrial
Sign In

Application and Mechanistic Study of Epigenetic Biomarkers and Multimodal MRI in the Prediction, Early Diagnosis, and Therapeutic Evaluation of Diabetic Neuropathic Pain

Application and Mechanistic Study of Epigenetic Biomarkers and Multimodal MRI in the Prediction, Early Diagnosis, and Therapeutic Evaluation of Diabetic Neuropathic Pain

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129239
Enrollment
Unknown
Registered
2026-08-01
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic neuropathic pain group

Interventions

Diabetes mellitus group:None
Diabetic neuropathic pain group:None
Healthy group:None

Sponsors

The Second Hospital,University of South China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Adult patients diagnosed with type 2 diabetes mellitus and patients diagnosed with diabetic neuropathic pain;

Exclusion criteria

Exclusion criteria: 1.Patients with malignant tumors, other metabolic diseases, endocrine disorders, or congenital or hereditary diseases;

Design outcomes

Primary

MeasureTime frame
Diagnostic status of diabetic neuropathic pain;—

Secondary

MeasureTime frame
Expression levels of epigenetic biomarkers in peripheral blood;Multimodal magnetic resonance imaging parameters;Expression levels of candidate biomarkers in cerebrospinal fluid;—

Countries

China

Contacts

Public ContactLiu Wenjie

The Second Hospital,University of South China

149144040@qq.com+86 734 8899735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026